Upcoming Investor Events from Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a pioneering company in the field of gene editing, has announced its participation in two significant investor events coming up this November. These events will provide vital insights into the company’s advancements in gene therapies and operational performance. Investors can look forward to exciting updates that reflect Intellia’s commitment to revolutionizing medicine through its innovative CRISPR-based approaches.
Third Quarter 2024 Financial Results Presentation
The first event is scheduled for November 7, where Intellia will present its third quarter financial results for 2024 at 8 a.m. ET. This presentation will cover not only the financial metrics but also operational highlights that underscore the company’s progress and future direction.
How to Join the Financial Call
Investors interested in joining the financial call should dial in approximately five minutes before the start time. U.S. callers can reach the conference by calling 1-833-316-0545, while international callers should use 1-412-317-5726. It’s essential for all participants to request access to the Intellia Therapeutics conference call when they connect.
Clinical Data Update on nexiguran ziclumeran
The second key event will take place on November 16 at 11 a.m. CT / 12 p.m. ET, featuring a webcast that will present new clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z), an investigational therapy for transthyretin (ATTR) amyloidosis. This event follows the company’s participation in the American Heart Association (AHA) Scientific Sessions, happening from November 16-18.
Understanding nexiguran ziclumeran
Nex-z represents a breakthrough therapy in the treatment landscape of ATTR amyloidosis. This innovative solution is engineered to provide a single-dose treatment option. Intellia is dedicated to developing and commercializing nex-z in collaboration with Regeneron, highlighting the synergy between the two companies in advancing gene editing technology.
Accessing the Webcast and Replay Options
For those looking to join the webcast on November 16, access will be available via Intellia’s website. Interested parties can visit their Events and Presentations page for the livestream and future updates. Additionally, a replay of both investor events will be made accessible on the company’s website for a minimum of 30 days following each presentation, allowing investors to catch up on what they may have missed.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is at the forefront of the clinical-development landscape, utilizing advanced CRISPR technology. The company aims to change how we treat genetic diseases through its in vivo programs, which uniquely edit disease-causing genes directly within the human body. Meanwhile, its ex vivo approaches focus on modifying human cells outside of the body to tackle cancer and autoimmune conditions. Intellia's commitment to pioneering new treatments is reinforced by its strong scientific and clinical expertise.
Continuous Innovation and Collaboration
As the field of gene editing expands, Intellia is actively working on enhancing its CRISPR technologies. Their research not only aims to refine editing capabilities but also to improve delivery methods, unlocking the potential for transformative therapies and improved patient outcomes.
Frequently Asked Questions
What events will Intellia Therapeutics hold in November?
Intellia will present its third quarter financial results and provide an update on its clinical data from the Phase 1 study of nexiguran ziclumeran.
How can I participate in Intellia’s investor events?
Investors can join the calls by dialing the specified numbers and accessing the webcast through Intellia’s Events and Presentations page.
What is nexiguran ziclumeran's role in medical treatment?
Nex-z is an investigational gene editing therapy aimed at treating transthyretin (ATTR) amyloidosis, designed to be administered as a single-dose.
Where can I find information about Intellia’s research?
Intellia provides updates on its research projects and clinical advances on its official website.
How long will the replays of events be available?
Replays of both events will be available for at least 30 days, ensuring investors can stay informed.
